Ludwig Enterprises and Emerson Urology
Associates Plan Bladder Cancer BCG Immunotherapy
Study
Ludwig
Prepares Major Patent Filing
SPARKS, NV
-- September 20, 2022 -- InvestorsHub NewsWire
-- (OTC
PINK:LUDG) Ludwig
Enterprises, a leading-edge innovator of genetic
inflammatory biomarkers to diagnose and manage chronic
diseases, is pleased
to announce that the Company has started discussions with Emerson
Urology Associates, Concord, MA regarding initiation of a clinical
study to evaluate the response of bladder cancer patients to BCG
immunotherapy. A confidentiality agreement has been signed with
Dr. John Libertino,
MD, Director of Emerson Urology Associates.
Bladder cancer is
the sixth most common cancer in the United States and the ninth
most common worldwide. Cancers of the bladder make up about 5% of
new U.S. cancer cases yearly, mostly in older people. In 2021, an
estimated 83,000 new cases will be diagnosed and approximately
17,000 deaths in the U.S. alone. Standard treatment for bladder
cancer patients with invaded muscle tissue includes cisplatin-based
chemotherapy followed by surgical removal of the bladder or
radiation therapy and concomitant chemotherapy.
An additional
treatment approach is an immunotherapy, a
class of treatments that uses a person's immune system to help kill
cancer cells. Bacillus Calmette-Guérin (BCG) is a cancer vaccine
that uses weakened bacteria to stimulate the immune system. BCG has
received U.S. FDA approval for the treatment of early-stage bladder
cancer.
The objective of
the joint research program between Ludwig Enterprises and Emerson Urology
Associates is to use Ludwig's proprietary genetic
inflammatory markers to study patients with early-stage superficial
bladder cancer and assess therapeutic response to BCG
immunotherapy.
Ludwig's
proprietary genetic inflammatory biomarker panel is in the process
of being submitted to the U.S. Patent office.
"This innovative
research study has the potential to create a predictive model of
early-stage cancer occurrence at a presymptomatic stage and show
which patients will respond to specific anticancer chemotherapy,"
stated Dr. Marvin S. Hausman
MD, Chairman of Ludwig's Scientific Advisory Board (SAB).
"In essence, Ludwig has developed a proprietary language that has
the potential to capture a snapshot of disease and the body's
response to treatment."
"Early diagnosis of urologic cancer and
ability to predict anticancer response has been a dream of mine for
a long time," said Dr. John Libertino, MD, Director of Emerson
Urology Associates." I am looking forward to seeing the clinical
results from this collaborative relationship."
About Ludwig Enterprises,
Inc.: Ludwig is an
innovative technology and health-related company that uses
inflammatory genetic markers to diagnose disease, diagnose, and
assess pre- and post-treatment responses. Initial clinical programs
will include but not be limited to cardiac disease, preeclampsia,
breast cancer, colon cancer, and bladder cancer.
About Emerson Urology
Associates: Our
Urologists provide
comprehensive medical and surgical services for urologic
conditions, offering today's most advanced diagnostic and treatment
expertise.
SAFE HARBOR
Forward-looking statements in this release
are made under the "safe harbor" provision of the Private
Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s
forward-looking statements are not a guarantee of future
performance. This news release includes forward-looking statements
concerning the future level of business for the parties. These
statements are necessarily subject to risk and uncertainty. Actual
results could differ materially from those projected in these
forward-looking statements due to certain risk factors that could
cause results to differ materially from estimated results.
Management cautions that all statements as to future results of
operations are necessarily subject to risks, uncertainties, and
events that may be beyond the control of Ludwig Enterprises, Inc.,
and no assurance can be given that such results will be achieved.
Potential risks and uncertainties include, but are not limited to,
the ability to procure, appropriately price, retain, and complete
projects and changes in products and competition.
CONTACT:
Ludwig Enterprises,
Anne Blackstone,
786-235-9026
or
HQ@ludwigent.com
SOURCE: Ludwig
Enterprises, Inc.